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Clinical trials on the use of COVID-19 convalescent plasma remain inconclusive. While
data on safety is increasingly available, evidence for efficacy is still sparse. Subgroup
analyses hint to a dose-response relationship between convalescent plasma neutralizing
antibody levels and mortality. In particular, patients with primary and secondary antibody
deficiency might benefit from this approach. However, testing of neutralizing antibodies is
limited to specialized biosafety level 3 laboratories and is a time- and labor-intense
procedure. In this single center study of 206 COVID-19 convalescent patients, clinical
data, results of commercially available ELISA testing of SARS-CoV-2 spike-IgG and –IgA,
and levels of neutralizing antibodies, determined by plaque reduction neutralization testing
(PRNT), were analyzed. At a medium time point of 58 days after symptom onset, only
12.6% of potential plasma donors showed high levels of neutralizing antibodies
(PRNT50 ≥ 1:320). Multivariable proportional odds logistic regression analysis revealed
need for hospitalization due to COVID-19 (odds ratio 6.87; p-value 0.0004) and fever
(odds ratio 3.00; p-value 0.0001) as leading factors affecting levels of SARS-CoV-2
neutralizing antibody titers in convalescent plasma donors. Using penalized estimation, a
predictive proportional odds logistic regression model including the most important
variables hospitalization, fever, age, sex, and anosmia or dysgeusia was developed.org January 2021 | Volume 11 | Article 6289711
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Frontiers in Immunology | www.frontiersin.The predictive discrimination for PRNT50 ≥ 1:320 was reasonably good with AUC: 0.86
(with 95% CI: 0.79–0.92). Combining clinical and ELISA-based pre-screening,
assessment of neutralizing antibodies could be spared in 75% of potential donors with
a maximal loss of 10% of true positives (PRNT50 ≥ 1:320).Keywords: COVID-19, SARS-CoV-2, immunodeficiency, antibody deficiency, coronavirus disease 2019,
convalescent plasma, SARS-CoV-2 neutralizing antibody, plaque reduction neutralization testINTRODUCTION
Convalescent plasma therapy has been advocated since the
beginning of the global spread of SARS-CoV-2 (1). Historically,
convalescent plasma was applied in different diseases, including
influenza, SARS, and MERS (2–4). Rapid availability and low costs
of convalescent plasma therapy have spurred researchers worldwide
to focus on this treatment approach. Alone in the US, convalescent
plasma was used in >40,000 COVID-19 patients generating strong
safety data (5). While observational findings in cases or smaller
cohorts appeared promising, reporting improved survival,
radiological resolution and viral load (6–8), data from two
randomized controlled trials in China and the EU, were
terminated prematurely, underpowered and unable to prove
clinical benefit (9, 10). In a recently completed randomized
controlled trial from India the majority of patients (~70%)
received plasma with low levels of SARS-CoV-2 neutralizing
antibodies (<1:80) (11). However, subgroup analyses report a
dose-response relationship between convalescent plasma
neutralizing antibody level and mortality, suggesting that
treatment with high levels of neutralizing antibodies is likely to be
more beneficial and advocating the administration of accordingly
selected plasmas in clinical trials (12). Based on pathophysiological
considerations and first case reports, it is expected that in particular
patients with deficient antibody production may be more likely to
benefit from convalescent plasma treatment (13, 14).
Identifying adequate donors is of critical importance for any
ongoing trials and centers actively recruiting convalescent
plasma donors. Collection of convalescent plasma is highly
regulated by national authorities requiring, e.g., different
periods for quarantine before convalescent plasma donation
and for storage before approval for use in COVID-19 patients.
Levels of neutralizing antibodies required for prevention or
treatment in COVID-19 remain to be determined. However,
based on general pathophysiological considerations it seems
plausible to use higher levels of antibodies and FDA and EMA
advocate levels of at least 1:80 to 1:160 and preferably higher
titers (15). Unfortunately, evaluating neutralizing antibody
capacities requires highly specialized expertise, availability of a
biosafety level 3 laboratory and is time- and labor-intense.
Consequently, and despite significant variability between
different commercially available ELISA tests, these tests are
applied frequently as a surrogate marker for the levels of
neutralizing antibodies (16).
In order to assess convalescent plasma therapy in COVID-19,
characterization of convalescent plasma by neutralizing antibody
capacities is indispensable for interpretation of safety andorg 2efficacy. Preference should be given to donors of COVID-19
convalescent plasma with the higher neutralizing antibody
response. Multiple assays for the detection of anti-SARS-CoV-
2 antibodies are available, including several systems for high-
throughput testing (17–20). These assays, although not of major
importance in standard care settings, but can support clinicians
to assess immune response in patients and are an important tool
in epidemiological studies (21). The gold-standard to assess the
neutralizing capacity of serum antibodies is the plaque-reduction
neutralization test by using wild type virus isolates. However, this
test needs access to wild-type isolates and BSL3 capacity,
including trained personnel. Recently, PRNT surrogate assays,
such as pseudotype-based neutralization assays (22) and
surrogate virus neutralization test (sVNT) were established
showing promising performance (23, 24). However, algorithms
without multiple and complex test systems may streamline the
identification process of adequate plasmas donors.
In this single center study, we characterized potential
COVID-19 convalescent plasma donors for presence of IgG-
and IgA-antibodies to the S1 domain of the SARS-CoV-2 spike
(S) protein by ELISA and for neutralizing antibody capacity
determined by plaque reduction neutralization test (PRNT).
Furthermore, by correlating these results with clinical data we
aimed to identify a clinical vignette that would help to improve
the donor selection process. We prefer donors with a PRNT50 of
≥1:320 enabling to achieve a neutralizing antibody titer
(PRNT50) of >1:40 with the administration of 440 ml of
convalescent plasma in recipients with <75 kg body weight or
660 ml of convalescent plasma in recipients with a body weight
of 75-110 kg (calculation example assuming 40 ml plasma
volume per kg body weight: 70 kg × 40 ml = 2800 ml; 440 ml
of convalescent plasma/(2800 + 440 ml) = 0.14; PRNT50 of
1:320 × 0.14 = 1:43 in the recipient).METHODS
Human Subjects and Serum Samples
In April 2020 we started screening patients who recovered from
mild to moderate COVID-19 for convalescent plasma donation.
Potential plasma donors were selected in agreement with
German national plasma donation guidelines. Required age
range is 18–60 years in first time donors and 18–68 in
experienced plasma donors, individual exceptions due to
extraordinary fitness and in absence of relevant comorbidities
can apply. According to national guidelines, convalescent
subjects required also to be clinically asymptomatic afterJanuary 2021 | Volume 11 | Article 628971
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The use of blood from healthy human subjects and from
COVID-19-convalescent subjects was approved by the
Institutional Review Board at Charité - Universitätsmedizin
Berlin (EA2/092/20 and EA2/066/20) (25). All patients
enrolled gave written informed consent in person.
Convalescent subjects had a history of SARS-CoV-2 infection
confirmed by a positive RT-PCR from pharyngeal swab.
Eligibility of potential donors was checked according to
national regulatory guidelines for plasma donors (Richtlinie
Hämotherapie) (26). Clinical data was collected using a
questionnaire for clinical symptoms including fever, dyspnea,
cough and anosmia/dysgeusia as well as for requirement for
hospitalization due to COVID-19. For serologic and
neutralization testing, 9-ml blood from each donor were
collected in serum tubes. Serum tubes were centrifuged at
1,500 g and 20°C for 15 min and aliquoted into 500- to 1,000-
ml aliquots and stored at −20°C until further processing.
Enzyme-Linked Immunosorbent Assay
for Anti-SARS-CoV-2 S1-IgG and -IgA
For the detection of IgG and IgA to the S1 domain of the SARS-
COV-2 spike (S) protein, anti-SARS-CoV-2 assay was used
according to the manufacturer´s instructions (Euroimmun,
Lübeck, Germany). Serum samples were tested at a 1:101
dilution using the fully EUROIMMUN Analyzer. Optical
density (OD) ratios were calculated by dividing the OD at 450
nm by the OD of the calibrator included in the kit. The calculated
OD ratios can be used as a relative measure for the concentration
of antibodies in the serum. For IgG and IgA response, an OD
ratio < 1.1 was considered to be non-reactive.
Plaque Reduction Neutralization Test
for SARS-CoV-2
PRNTs for SARS-CoV-2 were performed as previously described
(27, 28). Briefly, Vero E6 cells were seeded in a 24-well plate
format. Sera were diluted and mixed with 100 plaque forming
units of SARS-CoV-2 (strain: SARS-CoV-2/human/DEU/
BavPat2-ChVir984, NCBI GenBank Acc. No. MT270112.1).
Each 24-well was incubated with serum-virus solution for 1 h
at 37°C. After 1 h, supernatants were discarded, cells were
washed once with PBS, and 1.2% Avicel solution in DMEM
was added to the wells. After 3 days at 37°C, all supernatants
were discarded and cells were fixed using a 6% formaldehyde/
PBS solution and stained with crystal violet. Serum dilutions with
a plaque reduction of 50% (PRNT50) are referred to as titers.
Statistical Analysis
All analyses were conducted in R (version 4.0.2.) using theHmisc
(version 4.4-0) and rms packages (version 6.0-0). For
proportional odds (PO) logistic regression on categories of
neutralizing SARS-CoV-2 antibody titers PRNT50 values for
1:320 (10 donors), 1:640 (7 donors), and 1:1,280 (9 donors) were
pooled into a single category (≥1:320) to gain sufficient per-
category sample sizes and 3 of 206 clinical records were excluded
due to missing entries in several variables. The full model wasFrontiers in Immunology | www.frontiersin.org 3prespecified to include variables sex, age in years, days after
positive SARS-CoV-2 RT-PCR testing, fever, dyspnea, cough,
anosmia/dysgeusia, and requirement for hospitalization. For
developing a predictive model, shrunken coefficients of the full
model were first re-estimated by L2-penalized regression and the
linear predictors approximated by ordinary linear regression and
step-down backward selection of the top 4 important predictors
with only minute loss of precision (R2 > 0.99 compared to full
model). Correct estimates of the variance of the coefficients of the
reduced model were calculated using equation 5.2 in (29).
A second PO logistic regression model was used to calculate
L2-penalized regression coefficients of anti-SARS-CoV-2 S1-IgG
OD ratios for higher SARS-CoV-2 neutralizing antibody titers.
Coefficients and covariance matrices of both models were used to
create spreadsheets (Supplementary Data Sheet 2 and 3) in large
adaptation of an example given by (30). Receiver-operator
characteristics were analyzed using the pROC package (version
1.16.2). Specificities at 0.95 target sensitivity and 95% confidence
intervals (CI) for all performance measures were computed with
2,000 stratified bootstrap replicates. The true positive number
after two consecutively performed tests A and B can be estimated
by TPAB = T × (SeA × SeB − covSeAB), with T the number of real
cases and the final serial-test sensitivity which is given by the
product of the individual tests’ sensitivities SeA and SeB, adjusted
by their conditional covariance covSeAB. The false positive
number calculates as FPAB = N × ((1 − SpA) × (1 − SpB) +
covSpAB), with N the number of real negative cases, and SpA, SpB
the individual tests’ specificities and their covariance covSpAB.
The final specificity of two consecutive tests can be estimated by
SpAB = SpA + SpB − SpA × SpB − covSpAB (31).RESULTS
Clinical Characteristics
Potential plasma donors contacted our clinic after being
diagnosed with COVID-19. General suitability for plasma
donation was evaluated before presentation at our clinic by
telephone interview. In total, 206 potential convalescent
plasma donors were assessed. In agreement with national
recommendations, all convalescent patients had a symptomatic
confirmed SARS-CoV-2 infection (mandatory positive SARS-
CoV-2 test by RT-PCR testing in pharyngeal swab). In addition,
patients required to be clinically asymptomatic after COVID-19
disease for at least 4 weeks.
All 206 donors were tested by ELISA for IgG and IgA against
SARS-CoV-2 S1 spike and by plaque reduction neutralization
test (PRNT50). In total, 54% of donors were female, and median
age of donors was 37.4 years. Median time point of antibody
testing was 53 days after positive SARS-CoV-2 PCR testing and
58 days after symptom onset. Patients were interviewed for
clinical symptoms including fever, dyspnea, cough, and
anosmia/dysgeusia. In addition, patients were asked to report
requirement for hospitalization due to COVID-19.
Fever was reported by 109 donors (53%), dyspnea by 70
donors (34%), cough by 130 (63%), and anosmia/dysgeusia byJanuary 2021 | Volume 11 | Article 628971
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reported by 19 donors (9%) (Table 1).
Detection of Anti-SARS-CoV-2 S1-IgG
and IgA by ELISA
Despite positive SARS-CoV-2 RT-PCR result, IgG-and IgA-
antibodies against S1 spike protein were only detectable in 89%
of donors. Using the manufactures cut-off for SARS-CoV-2 spike
ELISA with a ratio < 1.1, a total of 23 donors showed
seronegativity for both (IgG(−)/IgA(−)), 42 donors were IgG
(+)/IgA(−), six donors were IgG(−)/IgA(+).
Detection of Neutralizing Antibodies
by Plaque Reduction Neutralization
Test (PRNT50)
No detectable neutralizing SARS-CoV-2 antibodies (PRNT50 <
1:20) were found in 33 donors (16%). A PRNT50 of ≥1:20–<1:40
was detectable in 39 donors (19%), a value of≥1:40–<1:80was found
in 38 donors (18%), PRNT50 levels of ≥1:80–<1:160 were seen in 40
donors (19%), levels of ≥1:160–<1:320 in 30 donors (15%) and
PRNT50 levels ≥ 1:320 were detected in 26 (13%) (Table 1).
Correlation of Anti-SARS-CoV-2 S1-IgG
and IgA With Levels of Neutralizing
Antibodies (PRNT50)
SARS-CoV-2 neutralizing antibody titers significantly correlated
both with anti-S1 IgG and anti-S1 IgA antibodies (Figure 1).
Receiver-operator characteristics (ROC curves) for prediction of
a PRNT50 titer of at least 1:320 revealed only moderateFrontiers in Immunology | www.frontiersin.org 4discrimination when using anti-S1 IgA as predictor (AUC: 0.76
with 95% CI: 0.67–0.84, Figure 1A) whereas anti-S1 IgG
performed very well (AUC: 0.92 with 95% CI: 0.87–0.96,
Figure 1B).
Bivariate analyses using non-parametric rank correlation
coefficients further revealed strong association of PRNT50
titers with presence of fever and hospitalization status, the
latter of which positively correlated with other variables
indicative of disease severity, such as fever, dyspnea, age, and
time since positive PCR testing. A summarizing correlation
matrix between all variables analyzed is shown by heat plot
representation in Figure 2A.
Multivariable Analysis of Clinical
Features With Levels of Neutralizing
Antibodies (PRNT50)
Multivariable PO logistic regression analysis revealed need for
hospitalization for COVID-19 (odds ratio 6.87; p-value 0.0004)
and fever (odds ratio 3.00; p-value 0.0001) as leading factors
affecting levels of SARS-CoV-2 neutralizing antibody titers in
convalescent plasma donors (Table 2 and Figure 2B). Also
increasing age (odds ratio 1.32; p-value 0.0165) and male sex
(odds ratio 0.47; p-value 0.006) influenced neutralizing antibody
titers. There was a trend toward significance for anosmia/
dysgeusia (odds ratio 1.58; p-value 0.0847), while coefficients
for time point since RT-PCR positivity, dyspnea and coughing
were not significant in the model (Table 2 and Figure 2B).
Model for Neutralizing Anti-SARS-CoV-2
Antibody Levels to Tailor an Individual
Screening Strategy
Using penalized estimation, a predictive PO logistic regression
model including the most important variables age, sex, fever,
hospitalization, and anosmia or dysgeusia was developed (see
Supplementary Data Sheet 3). The predictive discrimination for
PRNT50 ≥ 1:320 was reasonably good with AUC: 0.86 (CI: 0.79–
0.92). Probabilities for PRNT50 ≥ 1:320 were modelled to
demonstrate effects of the individual predictors (Figure 2C).
Both male and female donors showed an increase of predicted
probability with increasing age. Female donors and fever during
COVID-19 resulted in a higher predicted probability for
PRNT50 ≥ 1:320. Predicted probability increased further when
donors were hospitalized for COVID-19 and additionally
developed anosmia or dysgeusia. The highest probabilities for
PRNT50 ≥1:320 can therefore be expected in male and female
patients aged 60 years or older with fever, previous
hospitalization for COVID-19 and accompanying anosmia
or dysgeusia.
In order to reduce labor and cost in performing plaque
reduction neutralization testing, a clinical prediction model
and anti-S1 IgG testing may be utilized with an appropriately
defined sensitivity for preselection with minute loss of donors
having potentially high neutralizing anti-SARS-CoV-2 antibody
titers (see Supplementary Material section).
Using the clinical vignette with a classification cutoff at 0.95
target sensitivity, approximately, one in four positively screenedTABLE 1 | Characteristics of COVID-19 convalescent plasma donors.
Total number of convalescent plasma donorsa 206
Median age in years (rangeb) 37.4
(18–74)
Female sex (%) 111 (54%)




Median time point after symptom onset in days (range) 58 (32–30)
SARS-CoV-2 antibodies:
Median SARS-CoV-2 S1-IgG ratio 2.9
Median SARS-CoV-2 S1-IgA ratio 1.77
Median PRNT50 (titer) 1:40
Convalescent plasma donors with PRNT50 <1:20 (%) 33 (16%)
Convalescent plasma donors with PRNT50 ≥1:20–<1:40 (%) 39 (19%)
Convalescent plasma donors with PRNT50 ≥1:40–<1:80 (%) 38 (18%)
Convalescent plasma donors with PRNT50 ≥1:80–<1:160 (%) 40 (19%)
Convalescent plasma donors with PRNT50 ≥1:160–<1:320 (%) 30 (15%)
Convalescent plasma donors with PRNT50 ≥1:320 (%) 26 (13%)
Clinical symptoms:
Convalescent plasma donors with fever (%) 109 (53%)
Convalescent plasma donors with dyspneac (%) 70 (34%)
Convalescent plasma donors with coughc (%) 130 (63%)
Convalescent plasma donors with anosmia/dysgeusiac (%) 111 (54%)
Convalescent plasma donors hospitalized for COVID-19 (%) 19 (9%)aAll donors were of Caucasian race/ethnicity, except a single Asian donor.
bTwo male donors were 70 and 74 years, all else were less than 65 years old.
cThree donors had missing entries for dyspnea, cough and anosmia/dysgeusia.January 2021 | Volume 11 | Article 628971
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positive predictive value (PPV) of 0.27 (CI: 0.19–0.34) and a
specificity of 0.62 (CI: 0.41–0.73). At 0.95 sensitivity, the anti-S1
IgG ELISA has 0.71 specificity (CI: 0.62–0.88) and a PPV of 0.32
(CI: 0.26–0.54), i.e., one in three donors tested above the
corresponding cutoff IgG OD ratio of 3.83 will have a PRNT50
titer of 1:320 or higher.
Aiming on gain in pre-screening specificity, i.e., to further
reduce numbers of false-positives that may enter PRNT, a serial
testing strategy can be devised where anti-S1 IgG ELISA is
performed only in donors that were positively classified in the
clinical vignette. Accepting 10% loss of donors with PRNT50 ≥
1:320 (i.e., 0.95 × 0.95 target sensitivity), conditional pre-
selection would result in a sensitivity of 0.89 (CI: 0.79–0.98), a
specificity of 0.85 (CI: 0.79–0.95) and a PPV of 0.46 (CI: 0.38–
0.72) corresponding to 23 true positive (CI: 21–25) and 27 false
positive (CI: 9–38) out of the 203 available donors in our study.
Thus, if anti-S1 IgG ELISA testing was performed in donors pre-
identified via the clinical vignette, analyzing PRNT could have
been spared in 75% of the donors of this cohort with the given
prevalence of 12.6% for PRNT50 titers ≥ 1:320.Frontiers in Immunology | www.frontiersin.org 5DISCUSSION
With the ongoing SARS-CoV-2 pandemic, convalescent plasma
continues to be a plausible treatment option, in particular for
patients with impaired specific SARS-CoV-2 antibody response
(e.g., primary and secondary immunodeficiency). Although data
showing clear efficacy is still missing, there is an increasing body
of evidence, that clinical benefit is linked to the neutralizing
capacity of convalescent plasma (12, 32–34). Selecting plasma
donors with high probability for higher levels of neutralizing
antibodies is therefore of importance for any ongoing or future
convalescent plasma trial.
While levels of neutralizing antibodies to MERS-CoV were
reported to remain stable for > 2 years (35), for SARS-CoV-2, it is
now recognized, that antibody levels are already declining after 3
months (36, 37). Therefore, identifying potential COVID-19
plasma donors is underlying additional time constraints.
In line with the highly variable disease course in COVID-19,
also humoral immune response expresses a great heterogeneity.
In this study higher levels of neutralizing antibodies (≥1:320 in
PRNT50) were only detectable in 12.6% of donors. DespiteA
B
FIGURE 1 | SARS-CoV-2 neutralizing antibody titers correlate with anti-S1 IgG and to a lesser extend with IgA antibodies. Plaque reduction neutralization test
(PRNT50) titers of 206 plasma donors were correlated with anti-S1 IgA (A) and anti-S1 IgG (B) ELISA measurements (r, Spearman’s rank correlation coefficients).
Values for 1:320, 1:640 (squares), and 1:1,280 (triangles) titers were pooled into a single category (≥1:320) to gain sufficient per-category sample sizes and to
represent the recommended minimum titer for convalescent plasma therapy (dashed vertical line). Dashed horizontal lines indicate ELISA positivity cutoffs provided
by the manufacturer EUROIMMUN). Right panels show receiver-operator characteristics (ROC curves) for prediction of a PRNT50 titer of at least 1:320 (AUC, area
under the curve).January 2021 | Volume 11 | Article 628971
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C
FIGURE 2 | Hospitalization, fever and age are main predictors of high SARS-CoV-2 neutralizing antibody titers in convalescent plasma. (A) Heat plot
representation summarizing bivariate rank correlation coefficients between all variables analyzed. Shown is only the upper triangle of the correlation matrix where
correlation coefficients are given as Spearman’s r for continuous variables (four leftmost columns) and Somers’ D for bivariate correlations including at least one
binary variable. Positive and negative correlations are colored in red and blue, respectively. Numbers within circles represent correlation coefficients expressed
as percent while circle sizes are proportional to the absolute correlation coefficient values. (B) Adjusted odds ratios (OR) estimated by multivariable proportional
odds (PO) logistic regression analysis are shown for each predictor of PRNT50 titer as response variable. OR of continuous variables are calculated for 4 weeks
increase in time since PCR+ and 10 years increase in age. Blue of different transparencies indicates 90, 95, and 99% confidence levels. (C) Predicted
probabilities for PRNT50 titers of at least 1:320 for varying predictor settings with 95% confidence bands. Shown are predicted probabilities for age ranging from
18 to 75 years in females (top row) and males (bottom row) by all possible combinations of hospitalization status with presence of anosmia or dysgeusia
(columns) and fever (blue and red lines). Effects were estimated by a L2-penalized PO logistic regression model including all shown, most important variables
age, sex, fever, anosmia or dysgeusia, and hospitalization.Frontiers in Immunology | www.frontiersin.org January 2021 | Volume 11 | Article 6289716
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swab, 11% of donors did not develop any detectable SARS-
CoV-2 S1-IgG or -IgA antibodies and 16% no detectable
neutralizing antibodies, respectively.
The availability of prescreening algorithms in order to
increase the probability of selecting plasma donors with higher
neutralizing antibody titers could support convalescent
plasma collection.
The assessment of clinical convalescent donor characteristics
is readily available and could serve as a “pre-test” filter. Our study
showed that in COVID-19 convalescent plasma donors, clinical
parameters of disease severity (i.e., need for hospitalization, fever
and anosmia or dysgeusia) as well as sex and age correlate with
levels of neutralizing antibodies against SARS-CoV-2. Using
additional ELISA tests, donors with a given level of
neutralizing antibodies, i.e., ≥1:320, may reliably be identified
with appropriate cutoffs.
Depending on the available local resources for testing
neutralizing antibody titers and depending on the availability
of convalescent plasma donors, i.e., high or low prevalence
regions, different sensitivities and specificities may be
preferred. Prediction models may help to develop an individual
screening strategy for potential convalescent plasma donors. In
our cohort, combining clinical vignette and IgG-ELISA, both
with a cutoff at target sensitivity of 95%, PRNT assays could be
spared in 75% of initial donors with the accepted loss of 10% of
true positives. Our observation of 13% high neutralizing
antibodies (PRNT50 of ≥1:320) is in line with recent reports
from smaller cohorts in the US and Europe, reporting 13%–
14.5% with PRNT50 of ≥ 1:500 (38, 39). In contrast, a recent
publication from Brazil showed a PRNT50 > 1:320 in
approximately 38% of donors, however donors were tested
earlier. Wendel et al, also highlighted that 36.2% of
convalescent plasma donors remained SARS-CoV-2 RT-PCR
positive within 28-48 days of recovery (40). Klein et al.
detected neutralizing antibodies (>1:20) in 80% but did not
report specifically on different titer dilutions (41).
Our results confirm that clinical severity (i.e., need for
hospitalization) and age predicts levels of neutralizing antibody
responses (41). In addition, we found that fever and anosmia/
dysgeusia correlates with neutralizing antibody titers which is
also supported by other studies (42–44). It remains inconclusive,
if and how sex correlates with neutralizing antibody responses inFrontiers in Immunology | www.frontiersin.org 7COVID-19 patients. In general, females develop more profound
adaptive immune responses against viral infections and vaccines
than males which might translate into the observed sex-
differences in SARS-CoV-2 pathogenesis and that may underly
reduced disease vulnerability in women (45–48). In patients with
moderate COVID-19, Takahashi et al. report (49) significantly
higher T cell activation and a trend for higher SARS-CoV-2-
specific antibody titers in female patients. While we and others
found that female donors had a higher probability of high
neutralizing antibodies (18, 50) or SARS-CoV-2 IgG antibodies
(49, 51, 52), other reports had the opposite finding (38, 41, 53–
56) or did not find a significance at all (39, 57, 58). These
seemingly contradictory findings might be due to sampling or
selection bias in individual studies but also to apparently
different dynamics in the SARS-CoV-2 neutralizing antibody
response in male and female donors (50, 59). Despite our finding
of higher antibody responses in female donors, it is important to
stress that female donors after pregnancy carry an elevated risk of
HLA- and HNA-antibodies. These antibodies are associated with
increased transfusion reactions resulting in the exclusion for
plasma donation. Generally excluding female donors would
therefore spare resource for these additional tests.
Our study has limitations. It is of cross-sectional nature, and
the narrow time window of sample collection with regard to
COVID-19 disease onset does not allow to analyze possible
kinetics of antibody responses. Results of our study are limited
to a specific ELISA test system recognizing antibodies against
spike protein, so we cannot apply our observations as a general
rule to other ELISA systems. Our analysis is not representative of
the humoral immune response to SARS-CoV-2 in all patients but
focuses on a rather homogeneous cohort of convalescent patients
that would qualify as plasma donors. Although application of our
prediction tool on a publicly available dataset (18) demonstrated
acceptable accuracy (Supplementary Data Sheet 4), predictive
performance may be worse in another clinical setting, e.g., due to
a different case-mix, thus requiring external validation and
potential recalibration of the prescreening model. In addition,
no standardization of the different neutralizing antibody assays
has been conducted. However, type of cell line, real virus or
pseudovirus, count of viral particles, culture volumes and other
factors are all likely to affect test results. It is therefore difficult to
compare levels of (neutralizing) antibodies to SARS-CoV-2 from
different studies.TABLE 2 | Multivariable proportional odds logistic regression analysis of factors affecting SARS-CoV-2 neutralizing antibody titers in convalescent plasma.
Factor c2 d.f. P-value OR (95% CI)
Time since PCR+ 0.65 1 0.4198 0.87 (0.61, 1.23)
Sex (male)* 7.55 1 0.0060 0.47 (0.28, 0.81)
Age* 5.75 1 0.0165 1.32 (1.05, 1.67)
Fever* 16.02 1 0.0001 3.00 (1.75, 5.14)
Dyspnea 0.07 1 0.7921 1.08 (0.61, 1.91)
Cough 0.08 1 0.7796 0.93 (0.55, 1.56)
Anosmia or Dysgeusia* 2.97 1 0.0847 1.58 (0.94, 2.67)
Hospitalized* 12.66 1 0.0004 6.87 (2.38, 19.88)
TOTAL 48.04 8 <0.0001January 2021 | Volume 1Wald statistics and adjusted odds ratios are shown for each predictor of PRNT50 titer as response variable (d.f., degrees of freedom; OR, odds ratio; CI, confidence interval). Odds ratios of
continuous variables are calculated for 4 weeks increase in time since PCR+ and 10 years increase in age. Asterisks indicate backward-selected variables for a final predictive model
(Figure 2C).1 | Article 628971
Schlickeiser et al. SARS-CoV-2 Neutralizing Antibody LevelsThe wide spectrum of antibody responses in convalescent
plasma donors with mild COVID-19 disease remains an
important issue. Our data support a clinical evaluation of
COVID-19 symptoms as a pre-filter in order to identify
convalescent plasma donors with potentially higher
neutralizing antibody levels. The availability of prescreening
algorithms in order to increase the probability of selecting
plasma donors with higher neutralizing antibody titers could
support convalescent plasma collection by sparing resources for
labor-intense testing of neutralizing antibodies.DATA AVAILABILITY STATEMENT
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SUPPLEMENTARY DATA SHEET 1 | ROC analysis for PRNT50 ≥1:320. This
Excel file contains two spreadsheets with receiver-operator characteristics for using
anti-SARS-CoV-2 S1-IgG OD ratio as predictor of PRNT50 titers ≥1:320, and for
using the PO logistic regression model with a four-variable clinical vignette (sex, age,
fever, anosmia/dysgeusia, and requirement for hospitalization) to predict PRNT50
titers ≥1:320, respectively. The spreadsheets list several performance measures for
a range of possible thresholds as given by each donor’s predicted value. These may
be used to identify classification cutoffs at a certain target value of a performance
measure, for example a sensitivity of 95%.
SUPPLEMENTARY DATA SHEET 2 | Predictive PO model for ELISA IgG OD
ratio. This Excel file contains spreadsheets to calculate probabilities of high PRNT50
titers using IgG OD ratio values as input. The first sheet provides a detailed
description of how this may be used. In short, IgG OD ratio values as determined
using Euroimmun anti-SARS-CoV-2 S1-IgG ELISA can be entered to calculate
probabilities of higher PRNT50 titers in sheets for either of the categories
“PRNT50>=320”, “PRNT50>=160”, “PRNT50>=80”, “PRNT50>=40”, or
“PRNT50>=20”, respectively. For example, in “PRNT50>=320” an estimated
probability higher than 0.06 (corresponding to IgG OD 3.83 for 95% target
sensitivity) would qualify a sample for inclusion into final plaque reduction
neutralization testing. For demonstration purposes, sheets are prefilled with data
from this study.
SUPPLEMENTARY DATA SHEET 3 | Predictive PO model for clinical data. This
Excel file contains spreadsheets to calculate probabilities of high PRNT50 titers
using a clinical vignette with four important variables as input. The first sheet
provides a detailed description of how this may be used. In short, patient
characteristics (sex, age, fever, anosmia/dysgeusia, and requirement for
hospitalization) can be entered to calculate probabilities of higher PRNT50 titers in
sheets for either of the categories “PRNT50>=320”, “PRNT50>=160”,
“PRNT50>=80”, “PRNT50>=40”, or “PRNT50>=20”, respectively. For example, in
“PRNT50>=320” an estimated probability higher than 0.1046 (for 95% target
sensitivity) would qualify a sample for inclusion into further anti-SARS-CoV-2 S1-IgG
ELISA screening or final plaque reduction neutralization testing. For demonstration
purposes, sheets are prefilled with data from this study.
SUPPLEMENTARY DATA SHEET 4 | Validation of Predictive PO using data
from Padoan et al. Padoan et al. (18) have assessed the performance of different
immunoassays for the detection of SARS-CoV-2 antibodies in comparison with
neutralization activity. For 68 plasma donors an anti-spike IgG assay as well as
PRNT testing was performed and results are publicly available in a dataset (60)
which is used here to demonstrate the utility of the Excel prediction-tool. Data
acquired at least 25 days after disease onset of 6 non-hospitalized and 22
hospitalized (12 moderate, 10 severe) recovered patients is used to calculate
performance measures for the prediction of having a PRNT50 titer of ≥1:320.
Accuracy (F-measure) was 0.79 for using the clinical vignette alone and 0.83 in
combination with anti-Spike IgG.REFERENCES
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